The experimental therapy stenoparib (2X-121) may help extend survival in people with hard-to-treat ovarian cancer, according to new clinical trial data announced by the therapy’s…
News
PANCREATIC CANCER
Atebimetinib yields ‘extraordinary’ results in pancreatic cancer trial
An experimental cancer therapy known as atebimetinib is delivering “extraordinary” results for patients with pancreatic cancer. New data from an ongoing Phase 2a clinical…
The European Commission has approved Voranigo (vorasidenib) for certain types of glioma, marking the arrival of a new targeted pill poised to change…
GYNECOLOGICAL CANCER
FDA decision on relacorilant for ovarian cancer expected in July
The U.S. Food and Drug Administration (FDA) has agreed to review Corcept Therapeutics’ application seeking approval of relacorilant to treat platinum-resistant ovarian cancer. The…
Combination treatment with Tecvayli (teclistamab-cqyv) and Darzalex Faspro (daratumumab and hyaluronidase-fihj) led to a 100% response rate for 49 people with newly diagnosed…
The National Comprehensive Cancer Network (NCCN), a nonprofit alliance of 33 cancer centers, included Revuforj (revumenib) in its clinical practice guidelines for treatment of relapsed or…
PANCREATIC CANCER
New blood test detects multiple cancers at early stages
A new blood test capable of detecting multiple cancers at earlier, more treatable stages is now available in the U.S. for $689, its developer said.
GYNECOLOGICAL CANCER
Elahere approved in Canada for hard-to-treat ovarian cancer
The gynecological cancer therapy Elahere (mirvetuximab soravtansine) is now approved in Canada for adults with platinum-based, chemotherapy-resistant, ovarian, fallopian tube, or primary peritoneal cancer…
Over a 15-year period, the median survival time for people with myeloma has nearly doubled, increasing from 2.4 years for those diagnosed in 2005…
The advocacy organization Blood Cancer United has teamed up with motor oil company Valvoline Global and auto racing group Hendrick Motorsports to raise awareness…
Recent Posts
- Phase 3 trial testing if oral pill can stop pancreatic cancer from returning
- Vyriad targets 2026 clinical trial for new experimental cell therapy VV169
- Olverembatinib and chemo show deep response in trial for Ph-positive ALL
- Pancreatic cancer treatment atebimetinib set for Phase 3 trial
- 1st trial participant receives Alpha DaRT radiation therapy for glioblastoma
